WebNovartis reimagines medicine to improve and extend people’s lives. Our medicines, which reached 766 million patients around the world in 2024, address most major disease … WebThe Novartis Board of Directors proposes to cancel 30,699,668 shares (repurchased under the authorizations of 28 February 2024 and 2 March 2024) and to reduce the share capital …
Integrated Report - Société Générale
WebKey Figures 2024 + 14 .7 % Net sales Currency-adjusted growth 30 .9 % EBITDA margin 10 basis points lower than prior year 809 Mio. Free cashflow (in CHF) +12.8% versus prior year 21 .34 Earnings per share (in CHF) +18.9% versus prior year 59 .0 % Payout ratio in the mid-range of the defined corridor -8 .4 % WebApr 14, 2024 · 766 million lives were touched by Novartis medicines in 2024, and while we’re proud of this, we know there is so much more we could do to help improve and extend people’s lives. We believe new insights, perspectives and ground-breaking solutions can be found at the intersection of medical science and digital innovation. howard beckett priti patel
Novartis Highlights Focus on Creating Value for Stakeholders and ...
Web2024 was no different — with numerous product approvals and launches across Pharmaceuticals and Diagnostics, we are continuing to impact the lives of millions around the world. Major approvals in the Pharmaceuticals Division in 2024 Europe11 Gavreto Tecentriq Venclexta/Venclyxto + azacitidine Actemra/RoActemra (COVID-19) Enspryng … WebNovartis is pioneering an approach called social, environmental and economic (SEE) impact valuation that aims to show the positive impact we bring to countries, health systems and … WebFull-Year 2024 Investor Update Downloads Full-Year 2024 Presentation PDF Full-Year 2024 Presentation with appendix PDF Annual Report 2024 PDF Finance Report 2024 PDF Geschäftsbericht 2024 PDF Finanzbericht 2024 PDF Investor updates Nine-month 2024 Investor Update Downloads Nine-month 2024 Presentation PDF howard becker quotes